USFDA18 Sept 2026, 07:00 pm
Shilpa Medicare Unit VII USFDA Inspection Concludes with One Observation
AI Summary
Shilpa Medicare Limited announced that its Unit VII, Analytical Services Division in Hyderabad underwent a USFDA Surveillance Inspection from September 16-18, 2026. The inspection concluded with a single procedural observation, which was not a repeat and did not relate to data integrity. The company plans to address this observation and submit a response within the stipulated timeline. Shilpa Medicare expects no material impact on its current business operations or supplies from this facility.
Key Highlights
- USFDA conducted a surveillance inspection at Shilpa Medicare's Hyderabad facility.
- One procedural observation was noted during the inspection.
- The observation is not a repeat and not related to data integrity.
- No material impact expected on business operations or supplies.
Price Impact
More from SHILPAMED